MetaCap

OmniAb Inc. (OABI)

NASDAQ: OABIHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD

4.66-0.37 (-7.36%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

OABI stock chart

Technical analysis

Key statistics

All statistics
Market cap
$679.71M
EPS (TTM)
-$0.34
52-week range
1.35 – 5.45
Day range
4.61 – 5.05
Volume / Avg
1.90M / 1.46M
Beta
—

52-week range

$1.35$5.45

OABI stock today

On Nov 20, OABI ended the session at $4.66, shedding $0.37 (7.36%), versus the S&P 500's 3.70% decline. Shares are 14.5% below their 52-week high of $5.45, set on Nov 9, 2026 and 245.2% above the 52-week low of $1.35, near the top of the past year's range. OABI is up 151.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 163.3%.

OmniAb has posted a net loss over the last twelve months (EPS of -$0.34), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About OmniAb

Company profile

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Industry
Biotechnology: Commercial Physical & Biological Resarch
CEO
Mr. Matthew W. Foehr
Headquarters
EmeryVille, CA
Employees
89
IPO year
2021
Website
omniab.com

Financial highlights

Full financials

In fiscal 2025, OmniAb generated $18.7 million in revenue, down 29.3% from fiscal 2024, its first annual decline since 2024. OmniAb reported a net loss of $64.8 million, compared with a loss of $62.0 million a year earlier. Operating margin was -369.5%.

OmniAb annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$18.67M$26.39M$34.16M$59.08M$34.75M
Growth-29.27%-22.75%-42.17%+70.02%—
Net income$-64.78M$-62.03M$-50.62M$-22.33M$-27.04M
EPS (diluted)$-0.57$-0.61$-0.51$-0.26$-0.33

Analyst forecast

Forecast

Consensus (7 analysts)

none

Avg. price target

$8.33+78.76%

  • Strong buy 0
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $12.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 30, 2026
EPS actual vs est.
$-0.12 vs $-0.12

OABI news

All OABI news

OmniAb peers

Health Care sector
OABI peer companies
CompanyPrice% ChgMarket capCompare
NRCNRC Health25.16+0.68%$533.93Mvs OABI
MXCTMaxCyte Inc.1.37+7.03%$141.45Mvs OABI
ABSIAbsci Corporation7.51-7.97%$1.30Bvs OABI
ONMDOneMedNet Corp Class A4.70+4.21%$29.15Mvs OABI
BIAFbioAffinity Technologies Inc.1.65-10.81%$3.00Mvs OABI
ISPCiSpecimen Inc.0.4563-13.58%$2.64Mvs OABI
ICLRICON plc186.71-1.92%$13.99Bvs OABI
CRLCharles River Laboratories International Inc.314.32-4.15%$15.06Bvs OABI

Indexes, lists and sector

OmniAb stock FAQ

What is OmniAb's stock price today?

OABI last traded at $4.66 as of Nov 20, 4:00 PM EST, down 7.36% on the day. Prices are delayed at least 15 minutes.

Who is OmniAb's CEO?

Mr. Matthew W. Foehr is the chief executive officer of OmniAb Inc., which has about 89 employees.

What is the OABI 52-week high?

The 52-week high for OABI is $5.45 and the 52-week low is $1.35. The stock is currently 14.5% below its high.

Compare OABI